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Background: Insertable cardiac monitors (ICMs) are used to continuously monitor the patient’s
electrocardiogram. In response to patient activation or based on automated device algorithms, arrhythmia
episodes are stored and automatically transmitted daily to the clinician. Thus, ICMs can be used
to diagnose arrhythmias in at-risk patients and in those with symptoms potentially attributable to
arrhythmias. The ICM described in this report has undergone a dramatic change in size and method
of insertion.
Methods: To evaluate the safety profile of the ICM procedure, we analyzed procedure-related adverse
events (AEs) from two separate trials: A controlled, nonrandomized multicenter study (Reveal LINQTM
Usability study) and a multicenter registry (Reveal LINQTM Registry) evaluating real-world experience.
For the Registry we reported all procedure-related AEs upon occurrence, whereas for the Usability study,
we reported events occurring during the first month of follow-up.
Results: The Usability study enrolled 151 patients (age 56.6 ± 12.1 years; male 67%) at 16 centers;
during follow-up, an infection was observed in 1.3% patients and a procedure-related serious AE (SAE)
in 0.7% patients. The Registry enrolled 122 patients (age 61.0 ± 17.8 years; male 47%) at seven centers;
during follow-up, an infection was observed in 1.6% patients and a procedure-related SAE in 1.6%
patients.
Conclusions: The cumulative experience from a controlled clinical trial and a “real-world” registry
demonstrate that the new ICM can be inserted with very low incidence of AEs. (PACE 2015; 38:1464–
1469)
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They are used to continuously monitor the heart
rhythm over a period of several years. This
allows for automatic detection and storage of
cardiac arrhythmias, such as atrial fibrillation
(AF), atrial tachycardia, ventricular tachycardia,
as well as episodes of bradycardia. Prior studies
in patients with unexplained syncope have
demonstrated that ICMs can be implanted safely,
have a diagnostic yield as high as 80%, and
are cost-effective.1–3 The addition of automated
device-based algorithms designed to detect AF
has expanded the use of ICMs to include AF
monitoring in patients with cryptogenic stroke,4
before and after rhythm control interventions,5–7
and help guide decisions regarding the optimal
duration of anticoagulation.8,9
ICM technology has evolved dramatically
since the original devices were released in the
late 1990s. One of the most obvious advances
has been the marked reduction in size of the
ICM. The first ICM (Medtronic Reveal, Medtronic
Plc., Minneapolis, MN, USA) was 19 × 61 ×
8 mm3 in size and was implanted subcutaneously
by performing a small incision with a scalpel, and
then suturing the device to underlying tissue in
order to minimize migration. The implantation
procedure was usually done in-hospital, in a
catheterization or an electrophysiology laboratory.
The latest iteration of the device (Reveal LINQTM,
Medtronic Inc.) that was used in this analysis is
only 7 × 45 × 4 mm3 in size, making it 87%
smaller than its predecessor. The LINQTM has a
3-year battery life, records cardiac information
automatically in response to detected arrhythmias
(or on demand based on patient activation), and
uses remote cardiac telemetry to transmit data to
the physician. The insertion technique has been
greatly simplified. The ICM is provided preloaded
in an insertion tool that is used to deliver the
device subcutaneously through a small incision
(<1 cm) that is then closed using surgical glue,
surgical tape, stitches, or staples.10
The first generation of ICM devices was
associated with an incidence of infection that was
reported to be as high as 2.3–4.3%.3,4,11–13 Given
the significant change in device size and insertion
procedure, we sought to evaluate whether these
modifications have favorably influenced the safety
profile of the current ICM. The safety results pre-
sented were obtained from two separate ongoing
trials: A controlled, nonrandomized multicenter
study (referred to here as Usability study), and




Both studies were designed and conducted in
accordance with the Declaration of Helsinki. The
Table I.
Patient Characteristics and Primary Indication for ICM
Patient Usability Registry
Characteristics (n = 151) (n = 122)
Age (years) 56.6 ± 12.1 61.0 ± 17.8
Male (n, %) 101 (66.9%) 57 (46.7%)
Primary indication for ICM (n, %)
Syncope 19 (12.6%) 63 (51.6%)
Palpitations 3 (2.0%) 5 (4.1%)
Ventricular tachycardia 0 (0.0%) 3 (2.5%)
Suspected AF 5 (3.3%) 17 (13.9%)
Cryptogenic stroke 1 (0.7%) 6 (4.9%)
AF ablation monitoring 104 (68.9%) 17 (13.9%)
AF management 19 (12.6%) 9 (7.4%)
Other 1 (0.7%) 8 (6.6%)
AF = atrial fibrillation; ICM = Insertable cardiac monitors.
local Institutional Review Boards (IRBs) or Ethics
committees approved the study protocols at each
participating site. All patients provided written
informed consent. No patient was coenrolled in
both studies.
The Reveal LINQTM Usability study is an on-
going, global, prospective, nonrandomized, mul-
ticenter trial (ClinicalTrials.gov, NCT01965899)
being conducted in Europe and Australia. It
enrolled 151 patients at 16 centers between
September 2013 and June 2014. The study has two
phases: During the first phase, 30 patients with
any indication for a LINQTM ICM were enrolled;
for the second phase, patients with a documented
history of AF who were candidates for ablation
were included.10
The Reveal LINQTM Registry is an ongo-
ing, global, nonrandomized, prospective post-
market surveillance registry (ClinicalTrials.gov,
NCT01524276) with planned enrollment of at
least 1,200 patients with ICM devices. The
first enrollment was in March 2014 and as of
March 2015, a total of 161 patients had been
enrolled. Patients eligible to receive an ICM were
enrolled either at preinsertion or within 48 hours
postinsertion. In order to accurately capture all
adverse events (AEs), we limited the analysis to
122 patients from seven centers who were en-
rolled for predevice insertion (Online Appendix).
Enrollment to date has occurred predominantly
(88%) in the United States and eligibility was
based on currently approved indications for use:
Clinical syndromes or situations at increased risk
of cardiac arrhythmias, and transient symptoms
suggesting a cardiac arrhythmia, such as dizziness,
palpitations, syncope, or chest pain.
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Study Procedures
For the Usability study, centers were
instructed to execute the insertion under guidance
from the study protocol using the provided inci-
sion and insertion tools. Two thoracic anatomical
locations were recommended for ICM insertion
over the fourth intercostal space on the left
hemithorax: (Best) 45°with the superior end of the
device positioned approximately 2 cm left lateral
from the sternal border, and (Good) approximately
2 cm parallel to the sternal border.14 Insertions
in the Usability study could take place either in a
catheterization or electrophysiology laboratory, an
operating room, or a clean room (an enclosed en-
vironment within a hospital meeting a recognized
cleanliness standard). In contrast, the Registry did
not specify either insertion procedure or site of
service. Patient sedation, use of local anesthetics,
wound closure method, the use of perioperative
prophylactic antibiotics, and ICM fixation (the
use of sutures to hold the device in place) were at
the physician’s discretion in both studies.
The Usability study required an in-office
follow-up visit at 30 days postinsertion. AEs were
classified by an AE advisory committee (AEAC)
and all procedure-related AEs reported within
the first month were included in this report.
For the Registry, procedure-related AEs were
reported upon occurrence and classified by the
investigators.
Data Analysis
A procedure-related AE was defined as a clin-
ical sign, symptom, or health condition that was
causally related to the device insertion procedure.
A procedure-related serious AE (SAE) was an AE
that led to death or a serious deterioration in
health as indicated by a life-threatening illness or
injury, permanent impairment of body function or
damage; in-patient or prolonged hospitalization,
medical or surgical intervention to prevent life-
threatening illness or an injury, or permanent
impairment to a body structure or body function.
In both studies, infections were defined based on
the physician’s assessment.
AE and infection rates were calculated by
dividing the number of patients with infections
or AEs by the number of patients in the
corresponding analysis cohort. Two-sided 95%
confidence intervals were calculated using the
Exact Binomial method. Subject baseline char-




The baseline characteristics of all patients
are summarized in Table I. The Usability study
enrolled 151 patients; one patient was explanted
and exited the study 13 days postdevice insertion.
The remaining 150 patients completed 1-month
follow-up. In the Registry, five of 122 patients
included in this analysis exited the study (Online
Appendix).
The mean age of patients in the Usability
study was 56.6 ± 12.1 years; 67% were men.
The primary indications for an ICM were AF
ablation monitoring (69%) and syncope (13%).
The mean age in the Registry was 61 ± 17.8 years;
46.7% were men. Approximately half (52%) of
Registry patients were prescribed the ICM due to
syncope; an additional 35% were implanted for
AFmanagement, monitoring of suspected AF (e.g.,
cryptogenic stroke), or AF ablation.
Table II shows the procedure characteristics
for the Usability study and the Registry.
Adverse Procedure-Related Events
Table III shows all procedure-related AEs for
both studies. In the Usability study, the AEAC
reported AEs in eight patients, of whom only one
(0.7%) was classified as serious. The solitary SAE
began as pain at the insertion site and progressed
to a perforation and spontaneous device explant
through the insertion site 13 days postdevice
insertion. The AEAC classified two additional
patients as having significant insertion site pain.
In one patient, the pain could be relieved with
an analgesic (paracetamol/acetaminophen); in the
other patient, the device had to be explanted
5.4 months postinsertion. Two patients were
classified as having superficial wound infections.
Both insertions were performed by the same
operator, and in both instances, removing the
surgical glue that had been applied at the time
of device insertion treated the infection. In
neither instance was the patient administered an
antibiotic for treatment or the device explanted.
These infections were reported at 4 days and
15 days postdevice insertion; both patients had
received preprocedural intravenous antibiotics,
and wound closure had been achieved with
either surgical glue or surgical glue and adhesive
strips. Both ICM insertions were performed in a
catheterization laboratory, within the first month
of study enrollment; they corresponded to the
second and third procedures, from a total of
eight, performed at that center. Two patients
experienced minor bleeding from the insertion
site; in both instances, application of pressure
resolved the bleeding. Finally, in one patient
clear fluid was reported to emanate from the
wound 26 days postdevice insertion; the physician
adjudication committee did not deem this event
to represent an infection. The infection rate in the
Usability study was 1.3%.
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Table II.
Procedure Characteristics
Procedure Characteristics Usability (n = 151) Registry (n = 122)
Location of procedure
Catheterization or electrophysiology lab 130 (86.1%) 94 (77.0%)
Clean room 15 (9.9%) 28 (23.0%)
Operating room 2 (1.3%) 0 (0.0%)
Practice office 1 (0.7%) 0 (0.0%)
Other† 3 (2.0%) 0 (0.0%)
Anesthesia
Local anesthetic 150 (99.3%) 98 (80.3%)
General anesthesia 4 (2.6%) 1 (0.8%)
Moderate intravenous sedation None 24 (19.7%)
None 1 (0.7%) 4 (3.3%)
Preprocedural antibiotics 73 (48.3%) 51 (41.8%)
Oral 12 (7.9%) NR
Intravenous 60 (39.7%) NR
Unknown 1 (0.6%) NR
None 78 (51.7%) NR
Incision site preparation prior to insertion
No 1 (0.7%) NR
Yes 150 (99.3%) NR
Betadine 48 (31.8%) NR
Chlorhexidine 73 (48.3%) NR
Isoniazid (antibacterial) 17 (11.3%) NR
Benzyl alcohol 11 (7.3%) NR
Unknown 1 (0.7%) NR
Use of provided incision tool 151 (100%) 76 (62.3%)
Use of provided insertion tool 145 (96.7%) 111 (91.0%)
Thoracic anatomical location
Best 139 (92.1%) 88 (77.2%)
Good 9 (6.0%) 6 (5.3%)
Other 3 (2.0%) 20 (17.5%)
Device fixation with sutures
Yes 22 (14.6%) 7 (5.7%)
No 129 (85.4%) 112 (91.8%)
Not specified 0 (0.0%) 3 (2.5%)
Wound closure method
Suture 64 (42.4%) 20 (16.4%)
Staples None 31 (25.4%)
Surgical glue 14 (9.3%) 29 (23.8%)
Adhesive strips 60 (39.7%) 85 (69.7%)
Other 13 (8.6%) 0 (0.0%)
Suture and adhesive strips or glue 11 (7.3%) 0 (0.0%)
Antibiotics postinsertion 13 (8.6%) 5 (4.1%)
†Other locations were patient room within the hospital, practice office, and outpatient clinic.
NR = not reported for some or all patients.
In the Registry, three procedure-related AEs
were reported; two of these three events were
classified as serious (1.6%; Table III). One
SAE was insertion site pain, which necessitated
device removal at the patient’s request 27 days
postinsertion. The other serious event was an
insertion site infection that resulted in pain and
drainage from the incision site and was treated
with device explantation 45 days postdevice
insertion. This particular patient had received
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Table III.
Comparison of Procedure-Related Adverse Events between the Two Studies
AE Rate SAE Rate
Study Key Term AE (Two-sided 95% CI) SAE (Two-sided 95% CI)
Usability (n = 151) Insertion site pain 3 2.0% (0.4%, 5.7%) 1 0.7% (0.0%, 3.6%)
Incision site complication 1 0.7% (0.0%, 3.6%) 0 0.0% (0.0%, 2.4%)
Minor bleeding 2 1.3% (0.2%, 4.7%) 0 0.0% (0.0%, 2.4%)
Wound infection 2 1.3% (0.2%, 4.7%) 0 0.0% (0.0%, 2.4%)
Registry (n = 122) Insertion site pain 1 0.8% (0.0%, 4.5%) 1 0.8% (0.0%, 4.5%)
Insertion site infection 2 1.6% (0.2%, 5.8%) 1 0.8% (0.0%, 4.5%)
The Exact method was used to calculate the confidence intervals.
AE = procedure-related adverse event; CI = confidence interval; SAE = procedure-related serious adverse event.
preprocedural antibiotics intravenously, the pro-
cedure had been performed in an electrophys-
iology laboratory, and the incision had been
closed using adhesive strips. Finally, a second
insertion site infection was not classified as
an SAE. Mild erythema was noted around the
incision site 10 days postdevice insertion; the
issue resolved completely following administra-
tion of oral antibiotics. This particular patient
received preprocedural intravenous, oral, and
topical antibiotics. The incision was closed using
adhesive strips and staples, and the insertion was
performed in a clean room. The two infections
occurred at different centers within the first
6 months of the Registry. The infection rate in the
Registry was 1.6%.
Overall, the combined cohort of 273 patients
had an infection rate of 1.5% (n = 4), an AE rate
of 4.0% (n = 11), and an SAE rate of 1.1% (n = 3).
These statistical summaries do not adjust for the
differences between the two studies.
Discussion
Following device iteration and miniatur-
ization accompanied by a change in insertion
technique, it is important to objectively assess the
safety of the ICM. This report, which includes
the largest group of patients (n = 273) inserted
with the miniaturized ICM to date, showed
that its insertion is associated with a low rate
of procedure-related SAEs and infections. Of
151 patients inserted with the ICM during the
Usability study, 99.3% had no SAEs during
1-month follow-up, and 98.7% were free of
infections. Furthermore, the results obtained so
far from the Registry indicate that real-world
complication rates agree with the rates observed in
the controlled clinical trial (98.4% without SAEs
and 98.4% without infections).
Infection rates have been consistently low as
follows: 1.3% and 1.6% for the Usability study
and the Registry, respectively. Moreover, out of
23 centers where ICM insertions were performed,
only three centers reported infections, one of
which accounted for two infection events. The fact
that three of four patients with infections were
among the first procedures performed in those
centers suggests that these events may be related
to physician inexperience with the insertion
procedure. Indeed, some procedure-related AEs
may occur when a new technology is adopted,
but their number is expected to decrease as users
become more experienced.
Some of the differences observed in procedure
characteristics may be explained by the fact
that these two studies were done in different
geographies (the Registry has mainly taken place
in the United States, whereas the Usability study
is European and Australian). However, our report
shows that despite the variation in methods
for closing the skin after the procedure, the
administration of perioperative antibiotics, and
whether participants were selected or not in a
controlled manner, the insertion procedure of
this miniaturized ICM has a very favorable safety
profile. Indeed, the infection rates are compa-
rable, and slightly lower, than those previously
reported with larger ICM models (of range 2.3–
4.3%).3,4,11–13
The main strength of our report is the
comparison of the ICM insertion as performed in a
controlled study and following protocol directions
with a real-world study, where procedures were
done at the physician’s discretion. Despite this,
infection and SAE rates were comparably low.
Additionally, the global nature of the data also
reinforces the favorable safety profile of the device.
On the other hand, one of the limitations was that
AE adjudication for the Registry was based on the
physician’s judgment. A second limitation is that,
unlike the Usability study, the Registry did not
have a scheduled follow-up visit within the first
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month after ICM insertion. This may be causing an
underestimation of AEs for which patients might
choose not to consult their physicians. However,
we think this may have a minimal impact
since patients were given the usual postsurgery
discharge instructions informing them to look for
signs/symptoms of infection. Finally, the study
design being different for both studies, elements
such as incision site preparation prior to insertion
and type of preprocedural antibiotics used were
not directly comparable.
Conclusions
This report assessed AEs related to the
insertion procedure of a miniaturized ICM in a
controlled clinical trial and a real-world product
surveillance registry, and demonstrated that the
device can be inserted with minimal associated
AEs. The changes made to the size and insertion
procedure of the ICM do not alter the safety
profile compared with earlier devices. On the
contrary, these changes are improvements that
have simplified the procedure and will allow
more patients to benefit from long-term cardiac
monitoring.
Acknowledgments: We would like to thank Baerbel
Maus, Shelby Li, Tracy Bergemann, and Brien Neudeck for
their contributions to the analysis and critical review of the
manuscript, aswell as all the LINQUsability and LINQRegistry
investigators for their hard work and participation in the
study.
References
1. Furukawa T, Maggi R, Bertolone C, Fontana D, Brignole M.
Additional diagnostic value of very prolonged observation by
implantable loop recorder in patients with unexplained syncope.
J Cardiovasc Electrophysiol 2012; 23:67–71.
2. KrahnAD, Klein GJ, Yee R, Hoch JS, SkanesAC. Cost implications of
testing strategy in patients with syncope: Randomized assessment
of syncope trial. J Am Coll Cardiol 2003; 42:495–501.
3. Krahn AD, Klein GJ, Yee R, Takle-Newhouse T, Norris C. Use of an
extendedmonitoring strategy in patients with problematic syncope.
Reveal investigators. Circulation 1999; 99:406–410.
4. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA,
Morillo CA, Rymer MM, et al. Cryptogenic stroke and underlying
atrial fibrillation. N Engl J Med 2014; 370:2478–2486.
5. Gersak B, Pernat A, Robic B, Sinkovec M. Low rate of atrial
fibrillation recurrence verified by implantable loop recorder
monitoring following a convergent epicardial and endocardial
ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2012;
23:1059–1066.
6. Hanke T, Charitos EI, Stierle U, Karluss A, Kraatz E, Graf B,
Hagemann A, et al. Twenty-four-hour Holter monitor follow-up
does not provide accurate heart rhythm status after surgical atrial
fibrillation ablation therapy: Up to 12 months experience with
a novel permanently implantable heart rhythm monitor device.
Circulation 2009; 120:S177–S184.
7. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Turov A,
Shirokova N, Karaskov A. Ablation of paroxysmal and persistent
atrial fibrillation: 1-Year follow-up through continuous subcuta-
neous monitoring. J Cardiovasc Electrophysiol 2011; 22:369–375.
8. Mittal S, Pokushalov E, Romanov A, Ferrara M, Arshad A, Musat
D, Preminger M, et al. Long-term ECG monitoring using an
implantable loop recorder for the detection of atrial fibrillation after
cavotricuspid isthmus ablation in patients with atrial flutter. Heart
Rhythm 2013; 10:1598–1604.
9. Zuern CS, Kilias A, Berlitz P, Seizer P, Gramlich M, Muller K,
Duckheim M, et al. Anticoagulation after catheter ablation of
atrial fibrillation guided by implantable cardiac monitors. Pacing
Clin Electrophysiol 2015 (in press; doi: 10.1111/pace.12625. [Epub
ahead of print]).
10. Pu¨rerfellner H, Sanders P, Pokushalov E, Di Bacco M,
Bergemann T, Dekker LRC, Investigators ftRLUS. Minia-
turized reveal LinqTM insertable cardiac monitoring (ICM)
system: First inman experience. Heart Rhythm2015; 12:1113–1119.
11. Babikar A, Hynes B, Ward N, Oslizok P, Walsh K, Keane D. A
retrospective study of the clinical experience of the implantable
loop recorder in a paediatric setting. Int J Clin Pract 2008; 62:1520–
1525.
12. Seidl K, Rameken M, Breunung S, Senges J, Jung W, Andresen D,
van Toor A, et al. Diagnostic assessment of recurrent unexplained
syncope with a new subcutaneously implantable loop recorder.
Reveal-investigators. Europace 2000; 2:256–262.
13. Pachulski R, Cockrell J, Solomon H, Yang F, Rogers J. Implant
evaluation of an insertable cardiac monitor outside the




14. Medtronic Inc. Reveal Linq LNQ11 Insertable Cardiac
Monitor. Clinician Manual, 2014. Available at: http://www.
medtronicdiagnostics.com/us/education-resources/reveal-
manuals-mri-information/index.htm (accessed August 10, 2015).
Supporting Information
Additional Supporting Informationmay be found in the online version of this article at the publisher’s
website:
Appendix: Patient flow charts. (A) LINQTM Usability Study. (B) LINQTM Registry Wiley: Please check
“Supporting Information (Online appendix)” and its citations as typeset for correctness.Author: Please
check “Supporting Information (Online appendix)” for correctness.
PACE, Vol. 38 2015 1469
